New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)

NCT01482104 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

277

Enrollment

OTHER

Sponsor class

Conditions

Skin Neoplasms
Carcinoma, Basal Cell

Interventions

DRUG: MAL-PDT re-treatment
DRUG: usual MAL-PDT

Sponsor

Norwegian University of Science and Technology

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]